Halozyme Therapeutics (NASDAQ: HALO) reported Q4 EPS of $0.85, $0.13 better than the analyst estimate of $0.72. Revenue for the quarter came in at $189.6 million versus the consensus estimate of $165.19 million.

Financial Outlook for 2018

Halozyme reiterated its financial guidance of:

• Net revenue of $115 million to $125 million, including 25% to 30% royalty growth;
• Operating expenses of $230 million to $240 million;
• Operating cash burn of $75 million to $85 million; and
• Year-end cash balance of $305 million to $315 million

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.